RT Journal Article
SR Electronic
T1 Vitamin D3 Supplementation at 5000 IU Daily for the Prevention of Influenza-Like Illness in Healthcare Workers: A Randomized Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.16.22280047
DO 10.1101/2022.09.16.22280047
A1 van Helmond, Noud
A1 Brobyn, Tracy L.
A1 LaRiccia, Patrick J.
A1 Cafaro, Teresa
A1 Hunter, Krystal
A1 Roy, Satyajeet
A1 Bandomer, Brigid
A1 Ng, Kevin Q.
A1 Goldstein, Helen
A1 Mitrev, Ludmil V.
A1 Tsai, Alan
A1 Thwing, Denise
A1 Maag, Mary Ann
A1 Chung, Myung K.
YR 2022
UL http://medrxiv.org/content/early/2022/09/17/2022.09.16.22280047.abstract
AB Importance Vitamin D supplementation has been shown to reduce the incidence of acute respiratory infections in populations at risk. The COVID-19 pandemic has highlighted the importance of preventing viral infections in healthcare workers.Objective The aim of this study was to assess the hypothesis that vitamin D3 supplementation at 5000 IU daily reduces influenza-like illness (ILI), including COVID-19, in healthcare workers.Design We conducted an open label, randomized clinical trial wherein a random group of healthcare workers was invited to receive 5000 IU daily vitamin D3 supplementation for nine months, while other random healthcare workers served as passive controls. All healthcare workers were required to self-monitor and report to employee health for COVID-19 testing when experiencing symptoms of ILI. COVID-19 test results were retrieved.Setting The trial was conducted at a tertiary university hospital.Participants Out of 7,600 healthcare workers, two groups of 4,708 and 2,892 subjects were pre-randomized to the vitamin D3 intervention and passive control groups, respectively. Out of 4,708 intervention subjects approached, 299 with no history of hypercalcemia or nephrolithiasis were enrolled. Subjects who completed at least 2 months of supplementation to ensure adequate vitamin D levels were included in the analysis (n=255).Intervention Daily oral vitamin D3 gel capsules at 5000 IU for 9 months.Main Outcome and Measure The primary analysis compared the incidence rate of all ILI, while secondary analyses examined incidence rates of COVID-19 ILI and non-COVID-19 ILI. Incidence rates were compared between the vitamin D and control groups.Results Between October 2020 and November 2021, 255 healthcare workers (age 47±12 years, 199 women) completed at least two months of vitamin D3 supplementation. Five subjects were withdrawn due to adverse effects. The control group consisted of 2,827 workers. Vitamin D3 5000 IU supplementation was associated with lower risk of ILI (incidence rate difference: - 1.7×10-4/person-day, 95%-CI: -3.0×10-4 to -3.3×10-5/person-day, P = 0.015) and a lower incidence rate for non-COVID-19 ILI (incidence rate difference: -1.3×10-4/person-day, 95%-CI - 2.5×10-4 to -7.1×10-6 /person-day, P = 0.038). COVID-19 ILI incidence was not statistically different (incidence rate difference: -4.2×10-5/person-day, 95%-CI: -10.0×10-5 to 1.5×10-5/person-day, P = 0.152). An intention-to-treat analysis could not be performed due to low enrollment in the pre-randomized intervention group.Conclusion and Relevance Daily supplementation with 5000 IU vitamin D3 reduces influenza-like illness in healthcare workers.Trial Registration Clinicaltrials.gov, NCT04596657Question Can 5,000 IU of daily vitamin D3 prevent influenza-like illness in healthcare workers?Findings In this randomized controlled trial, 5,000 IU of once daily vitamin D3 over a 9-month period revealed that vitamin D3 supplementation was associated with a statistically significant lower risk of influenza-like illness (incidence rate difference -1.7 × 10-4 / person-day, 95%-CI - 3.0 × 10-4 to -3.3 × 10-5 / person-day, P = 0.0147).Meaning Daily supplementation with 5,000 IU vitamin D3 reduces influenza-like illness in healthcare workers.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: TLB, PJL, TC, BB, KQN, HG, DT and MAM have employment relationships with the Won Sook Chung Foundation; all authors had no financial relationships with any third party organizations that might have an interest in the submitted work in the previous three years; TLB is an unaffiliated member of the Cooper University Hospital Institutional Review Board and did not participate in any final decisions, nor did she participate in any votes regarding the study; no other relationships or activities are present that could appear to have influenced the submitted work; MKC is the president of the Won Sook Chung Foundation, and was not involved in the study design, subject consenting, data collection and analysis, decision to publish, or preparation of the manuscript. MKC was involved in the conceptualization of the study and review of the manuscript.Clinical TrialNCT04596657Funding StatementThis study was supported by an unrestricted grant from the Won Sook Chung Foundation. Funding was awarded to Cooper Health System, a New Jersey non-profit corporation. Grant Activity # 310500749. Vitamin D capsules were donated to the study by Res-Q, N3 Oceanic Inc, Pennsburg, Pennsylvania, USA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Cooper University Hospital Institutional Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.COVID-19coronavirus disease 2019ILIinfluenza-like illness